HCMV感染的抗氧化治疗与洁罗维注射液临床预防与治疗应用

人巨细胞病毒(HCMV)是疱疹病毒中最大也是最常见的一种,HCMV感染危害性大,亚洲与非洲地区的人群感染率高,目前临床仍缺乏专属性强的治疗药物。在其治疗过程中,抗病毒药物长期应用导致耐药问题存在,而机体免疫功能抑制与病毒耐药发生率关系密切,因此HCMV防治过程中,抗病毒抗氧化协同治疗势在必行。洁罗维注射液(阿昔洛韦氯化钠注射液Ⅱ)是一种"抗病毒+抗氧化+营养支持"三重作用机制的新型复方抗病毒输液,可提高机体免疫功能,降低病毒耐药性,有利于临床诸多科室HCMV感染的预防与治疗,具有极高的临床推广价值。     

慢病毒介导的下丘脑中过表达miR-505小鼠模型的构建

目的:本文用慢病毒定点注射的方法构建了在下丘脑中过表达mi R-505的小鼠模型,并利用荧光原位杂交方法在冰冻切片组织上快速检测mi RNAs,以确认慢病毒载体介导的mi R-505在丘脑中的表达能力。方法:实验小鼠在脑立体定位仪下定位到下丘脑位置,采用原位注射的方式进行慢病毒注射,注射后采用实时荧光定量RCR和应用了LNA探针和TSA系统的FISH(fluorescence in situ hybridization)技术,完成在慢病毒介导的mi R-505过表达老鼠下丘脑区域细胞中的mi R-505检测和示踪。结果:mi R-505慢病毒注射未成年小鼠下丘脑区5、10、20和40天后,均可检测到mi R-505在下丘脑区域的表达,且实验结果表明在慢病毒介导的过表达小鼠下丘脑注射部位,mi R-505表达量有明显的提高。结论:利用慢病毒注射未成年小鼠下丘脑脑区的方法,成功的建立了下丘脑中过表达mi R-505的小鼠模型,使用LNA标记探针的FISH方法探索mi RNA表达规律较稳定,且重复率高。     

低分子肝素联合丹参注射液治疗急性心肌梗死的临床研究

目的:观察低分子肝素联合丹参注射液治疗急性ST段抬高型心肌梗死的临床疗效及安全性。方法:按照随机原则将78例急性心肌梗死患者分成两组,在常规溶栓治疗的基础上,其中对照组39人采用低分子肝素治疗,治疗组患者在对照组治疗的基础上给予丹参注射液治疗,对两组临床费用、住院时间和冠脉再通进行评价。结果:治疗组的临床费用、住院时间和冠脉再通与对照组相比,有统计学差异(P0.05)。结论:低分子肝素联合丹参注射液治疗急性心肌梗死的临床疗效确切,值得临床推广。     

参芎葡萄糖注射液联合脑蛋白水解物治疗急性脑梗塞的疗效及对神经功能缺损和血液流变学的影响

目的:探析参芎葡萄糖注射液与脑蛋白水解物联合治疗急性脑梗塞患者的临床疗效和对神经功能、血液流变学的影响。方法:入选急性脑梗患者130例,随机分为两组各65例。对照组在常规治疗基础上使用脑蛋白水解物治疗,治疗组在常规治疗基础上不仅使用脑蛋白水解物,还加用参芎葡萄糖注射液治疗,比较两组患者的临床效果、神经功能缺损评分改变和血液流变学情况。结果:治疗组有效率显著高于对照组(P0.05);神经功能缺损评分治疗后均有下降,但治疗组下降幅度更大(P0.05);治疗组红细胞压积、血小板聚集率和纤维蛋白原均显著下降(P0.05),且同期相比,治疗组纤维蛋白原和红细胞压积下降幅度显著优于对照组(P0.05)。结论:参芎葡萄糖注射液与脑蛋白水解物联合治疗急性脑梗塞患者疗效确切,安全可靠,值得临床推广。     

不同效应室浓度舒芬太尼复合丙泊酚对Narcotrend的影响

目的:探讨靶控输注不同效应室浓度的舒芬太尼复合丙泊酚对Narcotrend指数(NI)的影响。方法:选择60例全麻患者,年龄40-60岁,体重指数30 kg/m2,ASAⅠ-Ⅱ级,随机分为4组(n=15):舒芬太尼效应室靶控浓度0.1 ng/m L(A组)、0.2 ng/m L(B组)、0.3 ng/m L(C组)、0.4 ng/m L(D组);各组舒芬太尼达效应室靶浓度5 min后给予丙泊酚1 mg/kg。记录实验过程中的血压、心率、血氧饱和度及NI。所有患者在实验结束后,均调整至适宜的麻醉深度,给与阿曲库胺,进行气管插管。结果:靶控输注舒芬太尼使各组的NI有不同程度的降低,随着靶控浓度的增加,降低幅度增大;单纯靶控输注舒芬太尼时,其效应室浓度与NI呈负相关,相关系数为-0.456。结论:舒芬太尼能降低NI,舒芬太尼效应室浓度与NI呈负相关。而舒芬太尼效应室浓度0.4 ng/m L复合丙泊酚后,NI反而呈短暂的上升,随后下降的现象。     

球结膜下注射不同浓度消旋山莨菪碱液对雏鸡形觉剥夺近视眼轴的影响

目的研究不同浓度消旋山莨菪碱液对雏鸡形觉剥夺近视眼轴的影响。方法 3日龄雏鸡60只右眼遮盖半透明塑料膜,随机分为6组:给药组4组,不同浓度消旋山莨菪碱液(0.05%组,0.1%组,1%组,2.5%组),隔天行右眼球结膜下注射,每次给药50μL,共4次;对照组为生理盐水组,注射方法同给药组;单纯形觉剥夺组,不做干预。8 d后观察药物对眼轴的影响。结果 2.5%浓度组右眼与左眼眼轴差异显著小于低浓度组及对照组(P<0.05),给药组未发现组织病理毒性。结论消旋山莨菪碱对雏鸡近视眼轴增长有一定抑制作用,无毒副作用,有一定浓度依赖性。     

氨溴索与碳酸氢钠序贯灌洗佐治支气管扩张感染疗效分析

目的探讨氨溴索与碳酸氢钠灌洗治疗支气管扩张反复感染的疗效及意义。方法将支气管扩张反复感染住院患者,分为灌洗组(常规治疗方法 +支气管局部注药灌洗34例)、对照组(常规治疗方法 38例),治疗2周后进行临床评估,随访半年。结果灌洗组总有效率与对照组相比差异有统计学意义(P<0.05),半年急性加重次数与对照组相比差异有统计学意义(P<0.01)。结论在常规治疗基础上局部氨溴索、碳酸氢钠序贯灌洗能提高支气管扩张感染疗效、减少半年急性加重次数、改善生活质量,通过改善微环境来维持菌群平衡值得借鉴、推广。     

Flow‐injection chemiluminescence method for the determination of chloramphenicol based on luminol–sodium periodate order‐transform second‐chemiluminescence reaction

A new chemiluminescence (CL) reaction was observed when chloramphenicol solution was injected into the mixture after the end of the reaction of alkaline luminol and sodium periodate or sodium periodate was injected into the reaction mixture of chloramphenicol and alkaline luminol. This reaction is described as an order‐transform second‐chemiluminescence (OTSCL) reaction. The OTSCL method combined with a flow‐injection technique was applied to the determination of chloramphenicol. The optimum conditions for the order‐transform second‐chemiluminescence emission were investigated. A mechanism for OTSCL has been proposed on the basis of the chemiluminescence kinetic characteristics, the UV‐visible spectra and the chemiluminescent spectra. Under optimal experimental conditions, the CL response is proportional to the concentration of chloramphenicol over the range 5.0 × 10^?7–5.0 × 10^?5 mol/L with a correlation coefficient of 0.9969 and a detection limit of 6.0 × 10^?8 mol/L (3σ). The relative standard deviation (RSD) for 11 repeated determinations of 5.0 × 10^?6 mol/L chloramphenicol is 1.7%. The method has been applied to the determination of chloramphenicol in pharmaceutical samples with satisfactory results. Copyright © 2011 John Wiley & Sons, Ltd.     

Determination of clomipramine by flow‐injection analysis with acidic potassium permanganate–formic acid chemiluminescence detection

A sensitive and simple chemiluminescent (CL) method for the determination of clomipramine has been developed by combining the flow‐injection analysis (FIA) technique, which is based on the CL intensity generated from the redox reaction of potassium permanganate (KMnO₄)–formic acid in sulphuric acid (H₂SO₄) medium. Under the optimum conditions, the linear range for the determination of clomipramine was 0.04–4 µg/mL, with a correlation coefficient of 0.9988 (n = 10) and a detection limit of 0.008 µg/mL (3σ), and the relative standard deviation (RSD) for 2.0 µg/mL clomipramine (n = 11) is 1.26%. The proposed method has been successfully applied to the determination of the studied clomipramine in pharmaceutical preparations. The possible reaction mechanism is discussed. Copyright © 2011 John Wiley & Sons, Ltd.     

Selective determination of human immunoglobulin G by flow‐injection chemiluminescence

A novel flow‐injection chemiluminescence method was developed for the selective determination of human immunoglobulin G (IgG) in the presence of thiomersal by changing the flow rates of peristaltic pump. The study was based on the independence and additivity of the CL signals of human IgG and thiomersal in the galangin–potassium permanganate–polyphosphoric acid system. In meantime, two equations relating to the concentrations of mixing solutions of human IgG and thiomersal vs the CL intensity were established and solved, on the basis of which the content of thiomersal included in samples was simultaneously determined too. The enhanced CL intensity was in proportion to concerntrations in the range 8.0 × 10^?7 to 8.0 × 10^?5 g/mL for human IgG and 1.0 × 10^?7 to 2.0 × 10^?6 g/mL for thiomersal with the detection limits of 5.0 × 10^?7 g/mL for human IgG and 6.0 × 10^?8 g/mL for thiomersal, respectively. The relative standard deviation for 1.0 × 10^?5 g/mL human IgG was 0.8% and for 2.0 × 10^?7 g/mL thiomersal it was 2.0% (n = 10). The proposed method was applied to determine three synthetic samples with recoveries of 91.5–109.5%. In addition, the possible chemiluminescence mechanisms are discussed as well. Copyright © 2010 John Wiley & Sons, Ltd.